Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Clarification concerning amoxicillin skin testing

Alalia Berry, MD, William W. Busse, MD

Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis Rafael Pasternack, MD, PhD, Heini Huhtala, MSc, Jussi Karjalainen,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Longitudinal variation of serum periostin levels in adults with stable asthma Ruth Semprini, MB BS, Rachel Caswell-Smith, MBChB, James Fingleton, PhD,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Badrul A. Chowdhury, MD, PhD

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Serum periostin is associated with type 2 immunity in severe asthma

Mothers' anxiety during pregnancy is associated with asthma in their children Hannah Cookson, MB, ChB, Raquel Granell, PhD, Carol Joinson, PhD, Yoav Ben-Shlomo,

Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease Sadeep Shrestha, PhD, Howard W. Wiener,

David F. Choy, BS, Guiquan Jia, MD, Alexander R. Abbas, PhD, Katrina B

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Allergy testing in predicting outcome of open food challenge to peanut

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Physician needs in health informatics: Just ask the docs

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Repeated Episodes of Anaphylaxis with Normal Serum Tryptase but Elevated Levels of Urinary Prostaglandin D2 Phillip Lieberman, MD The Journal of Allergy.

Cats and dogs and the risk of atopy in childhood and adulthood

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Risk of congenital malformations for asthmatic pregnant women using a long-acting β2- agonist and inhaled corticosteroid combination versus higher-dose.

Phillip Lieberman, MD, Michael Tankersley, MD

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Ovalbumin content of influenza vaccines

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

What is an “eosinophilic phenotype” of asthma?

Jeffrey M. Harris, MD, PhD, Christopher R

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Geographic variability in childhood asthma prevalence in Chicago

A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children Felicia A. Rabito, PhD, MPH, John C. Carlson,

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

John Leung, MD, Navneet Virk Hundal, MD, Aubrey J. Katz, MD, Wayne G

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Environmental factors and eosinophilic esophagitis

Safety and efficacy of repeated monthly carboplatin desensitization

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD, Heleen Scheerens, PhD, Joseph R. Arron, MD, PhD, Yanan Zheng, PhD, Wendy S. Putnam, PhD, Merdad V. Parsey, MD, PhD, Sean P. Bohen, MD, PhD, John G. Matthews, MB, BS, PhD Journal of Allergy and Clinical Immunology Volume 132, Issue 3, Pages 567-574.e12 (September 2013) DOI: 10.1016/j.jaci.2013.03.051 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Patient disposition. Journal of Allergy and Clinical Immunology 2013 132, 567-574.e12DOI: (10.1016/j.jaci.2013.03.051) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Percentage change in FEV1 from baseline to week 20: (A) mITT; (B) periostin-high patients; and (C) periostin-low patients. Journal of Allergy and Clinical Immunology 2013 132, 567-574.e12DOI: (10.1016/j.jaci.2013.03.051) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Kaplan–Meier plots of time to treatment failure: (A) mITT; (B) periostin-high patients; and (C) periostin-low patients. Journal of Allergy and Clinical Immunology 2013 132, 567-574.e12DOI: (10.1016/j.jaci.2013.03.051) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Percentage change in PEF from baseline to week 20: (A) mITT; (B) periostin-high patients; and (C) periostin-low patients. Journal of Allergy and Clinical Immunology 2013 132, 567-574.e12DOI: (10.1016/j.jaci.2013.03.051) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Median values of pharmacodynamic biomarkers during the study. Journal of Allergy and Clinical Immunology 2013 132, 567-574.e12DOI: (10.1016/j.jaci.2013.03.051) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Median change from baseline of pharmacodynamic biomarkers after treatment. Journal of Allergy and Clinical Immunology 2013 132, 567-574.e12DOI: (10.1016/j.jaci.2013.03.051) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions